Duke University and eGenesis team up on xenotransplantation

Pair announces research collaboration leveraging eGenesis’ genome engineering and transgenic production capabilities to conduct in-vivo testing of pancreatic islet cell xenotransplants
| 2 min read
Register for free to listen to this article
Listen with Speechify
0:00
2:00

CAMBRIDGE, Mass.—Organ transplantation is held up by one major factor, which is the availability and accessibility of compatible human organs. To be honest, the scarcity of human organs in general is a key bottleneck, beyond the issue of the whether an individual patient might reject an organ.

One company trying to address the global organ shortage is eGenesis, a biotechnology company using gene-editing technologies for the development of safe and effective human-compatible organs, tissues and cells.

Very recently, the company announced the start of a research collaboration with the Duke University School of Medicine in which the two organizations will evaluate gene-edited pancreatic islet cells in non-human primate recipients as a prerequisite to advancing to human clinical trials. This collaboration is in addition to an existing eGenesis partnership with Massachusetts General Hospital, initiated in 2017.

“There are 1.6 million Americans who live with type 1 diabetes and whose quality of life is greatly impacted by the monitoring of their glucose levels and the need for multiple insulin injections on a daily basis,” said Dr. Allan Douglas Kirk, who holds professorships in surgery, pediatrics and immunology at Duke . “With advancements in gene editing technology, there is now the potential of developing and safely transplanting human-compatible xeno-islet cells, which could allow these patients to reduce or eliminate their need for glucose monitoring and insulin injections. The research we will conduct at Duke will help determine whether a minimally-invasive approach into human clinical studies might be possible.”

Added Dr. Michael Curtis, president of research and development of eGenesis: “eGenesis’ mission is to develop human-compatible organs, tissues and cells to alleviate the organ shortage crisis and to improve the health and quality of life of all patients who could benefit from transplant. This collaboration with Duke, a leading transplant center with deep expertise in immunology and diabetes, will accelerate our research and provide validation of our xeno-islet cell program, leading to the evaluation in human clinical trials in patients with type 1 diabetes. We look forward to working with our new colleagues to advance the field of organ, tissue, and cell transplantation.”

The concept of xenotransplantation, or the transplantation of organs, tissue and cells from one species to another, has been explored for several decades, with the pig considered the most suitable donor species for humans. However, challenges related to molecular incompatibilities between species as well as virologic concerns have stymied the advancement of the field. The goal of eGenesis is to advance the field of transplantation and make available safe and reliable xeno organs, tissues and cells to patients in need.

The company uses gene editing technology such as CRISPR to directly address the key virology and immunology hurdles that have impeded xenotransplantation to date. Currently, eGenesis is advancing an initial product toward the clinic for kidney transplant, with the longer-term potential of addressing a broader organ recipient population and expanding the applicability of xenotransplantation into other areas such as cell therapy.

About the Author

Related Topics

Loading Next Article...
Loading Next Article...
Subscribe to Newsletter

Subscribe to our eNewsletters

Stay connected with all of the latest from Drug Discovery News.

Subscribe

Sponsored

Gold circles with attached purple corkscrew shapes represent gold nanoparticles against a black background.

Driving gene therapy with nonviral vectors 

Learn why nonviral vectors are on the rise in gene therapy development.
A 3D digital illustration of a viral spike protein on a cell surface, surrounded by colorful, floating antibodies in the background

Milestone: Leapfrogging to quantitative, high throughput protein detection and analysis

Researchers continuously push the boundaries of what’s possible with protein analysis tools.
Blue cancer cells attached to a cellular surface against a bright blue background in a 3D rendering of a cancer infection.

Advancing immuno-oncology research with cellular assays

Explore critical insights into immunogenicity and immunotoxicity assays for cancer therapies.
Drug Discovery News November 2024 Issue
Latest IssueVolume 20 • Issue 6 • November 2024

November 2024

November 2024 Issue

Explore this issue